Frågedatum: 1995-09-11
RELIS database 1995; id.nr. 11989, DRUGLINE
www.svelic.se

Utredningen som riktar sig till hälso- och sjukvårdspersonal, har utformats utefter tillgänglig litteratur och resurser vid tidpunkten för utredning. Innehållet i utredningen uppdateras inte. Hälso- och sjukvårdspersonal är ansvarig för hur de använder informationen vid rådgivning eller behandling av patienter.


Can anaemia or eosinophilia be caused by fluconazole (Diflucan) or clonazepam (Iktorivil) treatment



Fråga: Can anaemia or eosinophilia be caused by fluconazole (Diflucan) or clonazepam (Iktorivil) treatment?

A 42-year-old woman has developed an E-coli septicemia and also a candida septicemia after abdominal surgery. Therapy with fluconazole in high dose (400 mg daily) was initiated on March 15. A decrease in haemoglobin value from 119 g/l to 73 g/l was noted between March 21 and April 4. A slight increase in the count of eosinophilic granulocytes (0.55 x 10(9)/l was also seen. Except for fluconazole, the patient has also been given clonazepam in different doses from March 31.

Sammanfattning: Treatment with Iktorivil (clonazepam) is not reported to cause either anaemia or eosinophilia. Both anaemia and eosinophilia can occur during fluconazole therapy. However, these patients often have other underlying diseases or concomittant therapy that may also induce anaemia.

Svar: In the files of the Swedish Adverse Drug Reactions Advisory Committe (SADRAC) there are no reports of either anaemia or eosinophilia during clonazepam treatment.

In the last edition of a pharmacological textbook it is stated that therapy with fluconazole is well tolerated. Over the dose range of 50-400 mg daily, there is no relationship between dosage and extent of adverse events. "There are few data to suggest that fluconazole causes problem with the renal or haematological systems" according to (1).

In a recent treatment study of candidemia in patients without neutropenia, fluconazole in the dose of 400 mg daily was given to 103 patients and another 103 patients received treatment with amphotericin B. There was no significant difference in mortality between the groups but less toxicity with fluconazole than with amphotericin B. Two patients in the fluconazole group had to discontinue treatment due to increase in liver transaminases. Nothing was stated about anaemia or other haematological adverse reactions (2).

In a treatment study, 14 patients with AIDS and cryptococcal meningitis were given oral fluconazole 400 mg/day for 10 weeks (3). A fall in haemoglobin (> 2.0 g/l) was seen in 29 per cent of the patients according to a table in the paper. It is stated that a fall in baseline haemoglobin by more than 0.5 g/l was more common among patients on amphotericin B. The reason for the discrepancy between these figures is not clear and both 0.5 g/l or 2.0 g/l are very minimal haemoglobin changes.

There are no reports of anaemia or eosinophilia to SADRAC in connection with fluconazole treatment. According to the manufacturer, a total of 63 cases of anaemia could be identified in their data base. In two cases, anaemia appeared secondary to bleeding following fluconazole related thrombocytopenia (one case or a possible fluconazole-warfarin drug interaction (one case). In a total of nine cases there were no other obvious cause and a possible relationship to fluconazole therapy cannot be excluded. In the majority of the remaining cases anaemia did not appear to be related to fluconazole therapy (4).

According to the manufacturer a possible relationship between eosinophilia and fluconazole therapy could not be excluded in 4/5 cases following medical evaluation. The dosage of fluconazole was 200 mg/day and the duration of therapy at onset ranged from 25 days to 423 days. In non-clinical studies there were four cases of eosinophilia with no other obvious cause and a possible relationship to fluconazole therapy that could not be excluded (4).

The present case should be reported to the regional center of the SADRAC at Huddinge Hospital. 1 Dollery, Therapeutic drugs. 1991; 1: F92 2 Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J med 1994; 331: 1325-1330 3 Larsen RA, Leal MAE, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for crytpococcal meningitis in AIDS. Ann Intern Med 1990; 113: 183-187 4 Letter: Dr GG Gribko Regulatory Affairs Division, Pfizer New York

Referenser: